Eversept Partners
Latest statistics and disclosures from Eversept Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NTRA, GSK, QQQ, INSP, TEVA, and represent 43.01% of Eversept Partners's stock portfolio.
- Added to shares of these 10 stocks: QQQ (+$79M), GSK (+$34M), RVTY (+$32M), PFE (+$31M), VTRS (+$16M), INSP (+$15M), HUM (+$12M), MNKD (+$11M), TECH (+$10M), LLY (+$10M).
- Started 18 new stock positions in MOR, AFMD, LLY, CRBP, PFE, TVTX, MNKD, KPTI, NVRO, NVO. GH, TERN, VKTX, ALEC, VTRS, BKD, VINC, STOK.
- Reduced shares in these 10 stocks: SPY (-$47M), NTRA (-$43M), , ARGX (-$12M), ILMN (-$12M), KRYS (-$11M), HQY (-$6.0M), SNDX (-$6.0M), , WAT.
- Sold out of its positions in A, ILMN, ImmunoGen, BHVN, Affimed Therapeutics B V.
- Eversept Partners was a net buyer of stock by $122M.
- Eversept Partners has $1.5B in assets under management (AUM), dropping by 31.70%.
- Central Index Key (CIK): 0001697013
Tip: Access up to 7 years of quarterly data
Positions held by Eversept Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Eversept Partners
Eversept Partners holds 70 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Natera (NTRA) | 10.8 | $163M | -21% | 1.8M | 91.46 |
|
| GSK Sponsored Adr (GSK) | 10.8 | $162M | +26% | 3.8M | 42.87 |
|
| Invesco Qqq Tr Unit Ser 1 Put Option (QQQ) | 9.7 | $145M | +117% | 327k | 444.01 |
|
| Inspire Med Sys (INSP) | 6.0 | $90M | +19% | 421k | 214.79 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 5.7 | $85M | -2% | 6.0M | 14.11 |
|
| Vera Therapeutics Cl A (VERA) | 5.2 | $79M | -4% | 1.8M | 43.12 |
|
| Syndax Pharmaceuticals (SNDX) | 5.0 | $75M | -7% | 3.1M | 23.80 |
|
| United Therapeutics Corporation (UTHR) | 3.8 | $58M | 251k | 229.72 |
|
|
| PerkinElmer (RVTY) | 3.4 | $51M | +163% | 483k | 105.00 |
|
| Bio-techne Corporation (TECH) | 2.9 | $43M | +30% | 608k | 70.39 |
|
| Hca Holdings (HCA) | 2.3 | $35M | -9% | 104k | 333.53 |
|
| Healthequity (HQY) | 2.3 | $34M | -14% | 421k | 81.63 |
|
| Pfizer (PFE) | 2.0 | $31M | NEW | 1.1M | 27.75 |
|
| Celldex Therapeutics Com New (CLDX) | 2.0 | $30M | -5% | 711k | 41.97 |
|
| Community Health Systems (CYH) | 1.9 | $28M | +10% | 8.0M | 3.50 |
|
| Shockwave Med | 1.7 | $26M | +6% | 81k | 325.63 |
|
| Argenx Se Sponsored Adr (ARGX) | 1.4 | $22M | -36% | 55k | 393.72 |
|
| Tenet Healthcare Corp Com New (THC) | 1.2 | $19M | -6% | 176k | 105.11 |
|
| Ionis Pharmaceuticals (IONS) | 1.1 | $16M | +15% | 376k | 43.35 |
|
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 1.1 | $16M | -74% | 30k | 523.07 |
|
| Viatris (VTRS) | 1.0 | $16M | NEW | 1.3M | 11.94 |
|
| Vaxcyte (PCVX) | 0.9 | $14M | -15% | 197k | 68.31 |
|
| Humana (HUM) | 0.8 | $12M | +1756% | 36k | 346.72 |
|
| Protagonist Therapeutics (PTGX) | 0.8 | $12M | -23% | 412k | 28.93 |
|
| Taro Pharmaceutical Inds SHS (TARO) | 0.7 | $11M | +2% | 264k | 42.34 |
|
| Mannkind Corp Com New (MNKD) | 0.7 | $11M | NEW | 2.4M | 4.53 |
|
| Danaher Corporation (DHR) | 0.7 | $10M | 41k | 249.72 |
|
|
| Eli Lilly & Co. (LLY) | 0.7 | $10M | NEW | 13k | 777.96 |
|
| Zimvie (ZIMV) | 0.6 | $9.3M | +3% | 565k | 16.49 |
|
| Guardant Health (GH) | 0.6 | $9.3M | NEW | 450k | 20.63 |
|
| Brookdale Senior Living (BKD) | 0.6 | $8.7M | NEW | 1.3M | 6.61 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.6 | $8.4M | -5% | 354k | 23.65 |
|
| Immunovant (IMVT) | 0.6 | $8.3M | +124% | 256k | 32.31 |
|
| Novo-nordisk A S Adr (NVO) | 0.5 | $8.0M | NEW | 62k | 128.40 |
|
| Karyopharm Therapeutics (KPTI) | 0.5 | $7.6M | NEW | 5.0M | 1.51 |
|
| Puma Biotechnology (PBYI) | 0.5 | $7.6M | -15% | 1.4M | 5.30 |
|
| Anthem (ELV) | 0.5 | $7.5M | -4% | 14k | 518.54 |
|
| Travere Therapeutics (TVTX) | 0.5 | $7.4M | NEW | 956k | 7.71 |
|
| Centene Corporation (CNC) | 0.5 | $7.3M | -4% | 93k | 78.48 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.5 | $7.3M | -6% | 1.4M | 5.08 |
|
| Gossamer Bio (GOSS) | 0.5 | $7.1M | -6% | 6.0M | 1.18 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.4 | $6.7M | -38% | 2.3M | 2.87 |
|
| 2seventy Bio Common Stock (TSVT) | 0.4 | $6.3M | +3% | 1.2M | 5.35 |
|
| Sutro Biopharma (STRO) | 0.4 | $6.2M | +3% | 1.1M | 5.65 |
|
| Liquidia Corporation Com New (LQDA) | 0.4 | $5.8M | -42% | 396k | 14.75 |
|
| Nevro (NVRO) | 0.4 | $5.6M | NEW | 390k | 14.44 |
|
| Amarin Corp Spons Adr New (AMRN) | 0.4 | $5.5M | 6.2M | 0.89 |
|
|
| Merus N V (MRUS) | 0.4 | $5.4M | +3% | 120k | 45.03 |
|
| Icon SHS (ICLR) | 0.3 | $5.2M | 15k | 335.95 |
|
|
| Waters Corporation (WAT) | 0.3 | $4.7M | -50% | 14k | 344.23 |
|
| Stoke Therapeutics (STOK) | 0.3 | $3.9M | NEW | 290k | 13.50 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.2 | $3.5M | NEW | 89k | 39.24 |
|
| Krystal Biotech (KRYS) | 0.2 | $3.3M | -77% | 19k | 177.93 |
|
| Alector (ALEC) | 0.2 | $3.2M | NEW | 536k | 6.02 |
|
| Avantor (AVTR) | 0.2 | $3.2M | 125k | 25.57 |
|
|
| Iqvia Holdings (IQV) | 0.2 | $3.1M | 12k | 252.89 |
|
|
| Morphosys Sponsored Ads (MOR) | 0.2 | $3.0M | NEW | 166k | 18.14 |
|
| Miragen Therapeutics (VRDN) | 0.2 | $2.5M | +3% | 142k | 17.51 |
|
| Molina Healthcare (MOH) | 0.2 | $2.4M | -4% | 5.8k | 410.83 |
|
| Xoma Corp Del Com New (XOMA) | 0.2 | $2.3M | +3% | 97k | 24.05 |
|
| Inflarx Nv (IFRX) | 0.1 | $2.0M | 1.3M | 1.54 |
|
|
| Viking Therapeutics (VKTX) | 0.1 | $1.9M | NEW | 23k | 82.00 |
|
| Terns Pharmaceuticals (TERN) | 0.1 | $1.9M | NEW | 283k | 6.56 |
|
| Aerovate Therapeutics (AVTE) | 0.1 | $1.6M | +7% | 54k | 29.57 |
|
| Curevac N V (CVAC) | 0.1 | $1.6M | +3% | 516k | 3.03 |
|
| Repligen Corporation (RGEN) | 0.1 | $1.5M | -17% | 8.2k | 183.92 |
|
| Seres Therapeutics (MCRB) | 0.1 | $1.1M | -20% | 1.4M | 0.77 |
|
| Affimed N V Ordinary Shs New (AFMD) | 0.1 | $882k | NEW | 167k | 5.30 |
|
| Vincerx Pharma Com New (VINC) | 0.0 | $403k | NEW | 80k | 5.06 |
|
| Ac Immune Sa SHS (ACIU) | 0.0 | $369k | 125k | 2.96 |
|
Past Filings by Eversept Partners
SEC 13F filings are viewable for Eversept Partners going back to 2017
- Eversept Partners 2024 Q1 filed May 15, 2024
- Eversept Partners 2023 Q4 filed Feb. 14, 2024
- Eversept Partners 2023 Q3 filed Nov. 14, 2023
- Eversept Partners 2017 Q4 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q1 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q2 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q3 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q4 restated filed Nov. 8, 2023
- Eversept Partners 2019 Q1 restated filed Nov. 8, 2023
- Eversept Partners 2019 Q2 restated filed Nov. 8, 2023
- Eversept Partners 2019 Q3 restated filed Nov. 8, 2023
- Eversept Partners 2019 Q4 restated filed Nov. 8, 2023
- Eversept Partners 2020 Q1 restated filed Nov. 8, 2023
- Eversept Partners 2020 Q2 restated filed Nov. 8, 2023
- Eversept Partners 2020 Q3 restated filed Nov. 8, 2023
- Eversept Partners 2020 Q3 amended filed Nov. 8, 2023